ESTRO 2024 - Abstract Book

S1714

Clinical - Lung

ESTRO 2024

Conclusion:

SABR in the treatment of ES-NSCLC in patients with ILD appears feasible and relatively safe. However, there is a higher rate of oxygen requirement than in non-ILD patients. Patients should be made aware of this when making their decisions about treatment.